Filippo G.
- Country
- Italy
- Department
- Oncologia Medica Provinciale
Research Overview
- EORTC 2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
- Phase 3 Randomized Open-Label Study of OP-1250 Versus Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer Post-Endocrine and CDK4/6 Inhibitor Therapy
- Phase II Evaluation of Adjuvant Palbociclib Versus Chemotherapy in Elderly Patients with High-Risk ER+/HER2- Localized Breast Cancer
Data & Insights
Has run more than one trial at 185 of 546 partner sites.
Specializations
Early Stage Breast Cancer
Focused on developing treatments for patients with hormone receptor-positive (HR+) and HER2-negative breast cancer, particularly investigating extended endocrine therapy approaches and alternative treatment strategies for high-risk patients.
- Post-operative therapeutic interventions
- Extended adjuvant therapy optimization
- Endocrine therapy timing and sequencing
Specializes in evaluating novel therapeutic agents like camizestrant and palbociclib for early-stage disease management.
Advanced/Metastatic Breast Cancer
Expertise in treating advanced breast cancer with innovative combination therapies, including targeted approaches for specific molecular subtypes and hormone receptor-positive disease.
- Triple-negative breast cancer treatment
- BRCA-related metastatic disease
- Novel therapeutic combinations
Investigates cutting-edge treatments including immunotherapy and targeted molecular therapies for metastatic disease.
Specialized Therapeutic Approaches
Conducts research on treatment-specific symptoms and complications, including management of vasomotor symptoms in breast cancer patients undergoing hormone therapy.
- Symptom management strategies
- Quality of life interventions
- Targeted molecular therapies
Focuses on developing personalized treatment approaches based on molecular and genetic markers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.